Literature DB >> 32438502

Substance Use and Mental Health in Emerging Adult Vs Older Adult Men and Women With Opioid Use Disorder.

Celestina Barbosa-Leiker1,2, Aimee N C Campbell3, Martina Pavlicova4, Jennifer Scodes5, A Kathleen Burlew6, Mary Hatch-Maillette7, Sarah E Mennenga8, Shannon G Mitchell9, Patricia Novo8, Edward V Nunes3, John Rotrosen8, Shelly F Greenfield10.   

Abstract

BACKGROUND AND OBJECTIVES: We examined age differences across genders in clinical characteristics in emerging adult (≤25 years) vs older adult patients (26+ years) with opioid use disorder (OUD).
METHODS: Participants (N = 570; 30% female) entering a comparative effectiveness medication trial of buprenorphine vs extended-release naltrexone.
RESULTS: Differences in clinical characteristics in emerging adult vs older participants were similar across genders. However, women 26+ years reported more mental health problems compared with women ≤25, while men ≤25 years reported more mental health problems compared with men 26+ years. DISCUSSION AND
CONCLUSION: Different strategies for emerging adult and older patients seeking OUD treatment may be necessary to address psychiatric comorbidities that differ across genders in this population. SCIENTIFIC SIGNIFICANCE: Comprehensive psychiatric assessment should be systematically included in OUD treatment for all genders. Treatment should focus on the emerging adult developmental phase when appropriate, with psychiatric treatment tailored for women and men, separately, across the lifespan. (Am J Addict 2020;29:536-542).
© 2020 American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Year:  2020        PMID: 32438502      PMCID: PMC7657988          DOI: 10.1111/ajad.13059

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  11 in total

1.  Emerging adulthood. A theory of development from the late teens through the twenties.

Authors:  J J Arnett
Journal:  Am Psychol       Date:  2000-05

2.  Adolescent Community Reinforcement Approach outcomes differ among emerging adults and adolescents.

Authors:  Douglas C Smith; Susan H Godley; Mark D Godley; Michael L Dennis
Journal:  J Subst Abuse Treat       Date:  2011-08-09

3.  Age and gender trends in long-term opioid analgesic use for noncancer pain.

Authors:  Cynthia I Campbell; Constance Weisner; Linda Leresche; G Thomas Ray; Kathleen Saunders; Mark D Sullivan; Caleb J Banta-Green; Joseph O Merrill; Michael J Silverberg; Denise Boudreau; Derek D Satre; Michael Von Korff
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

4.  Emerging adult age status predicts poor buprenorphine treatment retention.

Authors:  Zev Schuman-Olivier; Roger D Weiss; Bettina B Hoeppner; Jacob Borodovsky; Mark J Albanese
Journal:  J Subst Abuse Treat       Date:  2014-05-20

5.  Testing a Matching Hypothesis for Emerging Adults in Project MATCH: During-Treatment and One-Year Outcomes.

Authors:  Jordan P Davis; Brandon G Bergman; Douglas C Smith; John F Kelly
Journal:  J Stud Alcohol Drugs       Date:  2017-01       Impact factor: 2.582

6.  Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults.

Authors:  Kelly R Peck; Taylor A Ochalek; Gary J Badger; Stacey C Sigmon
Journal:  Drug Alcohol Depend       Date:  2020-01-22       Impact factor: 4.492

7.  Treatment Retention and Outcomes with the Adolescent Community Reinforcement Approach in Emerging Adults with Opioid Use.

Authors:  Justine W Welsh; Lora L Passetti; Rodney R Funk; Jane Ellen Smith; Robert J Meyers; Mark D Godley
Journal:  J Psychoactive Drugs       Date:  2019-05-14

8.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

9.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen
Journal:  Lancet       Date:  2017-11-14       Impact factor: 79.321

10.  Drug Overdose Deaths Among Women Aged 30-64 Years - United States, 1999-2017.

Authors:  Jacob P VanHouten; Rose A Rudd; Michael F Ballesteros; Karin A Mack
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-01-11       Impact factor: 17.586

View more
  2 in total

1.  Feasibility and outcomes from an integrated bridge treatment program for opioid use disorder.

Authors:  James R Langabeer; Tiffany Champagne-Langabeer; Andrea J Yatsco; Meredith M O'Neal; Marylou Cardenas-Turanzas; Samuel Prater; Samuel Luber; Angela Stotts; Tom Fadial; Gina Khraish; Henry Wang; Bentley J Bobrow; Kimberly A Chambers
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-03-31

2.  Prevalence of Mental Health Disorders among Individuals Enrolled in an Emergency Response Program for Treatment of Opioid Use Disorder.

Authors:  Christine Bakos-Block; James R Langabeer; Andrea Yatsco; Marylou Cardenas-Turanzas; Tiffany Champagne-Langabeer
Journal:  Subst Abuse       Date:  2020-12-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.